论文部分内容阅读
目的 评价泰素联合卡铂化疗和同步放疗在局部晚期非小细胞肺癌治疗中的疗效和毒性反应。方法 自 1996年 7月至 1998年 6月 ,15例不能手术的初治局部晚期非小细胞肺癌患者行泰素联合卡铂化疗和同步放疗。ⅢA期 7例 (47% ) ,ⅢB期 8例 (5 3% ) ;鳞癌 14例 (93 % ) ,腺癌 1例 (7% )。在放疗开始的第 1天、第 15天和第 2 9天分别给予泰素 40mg/m2 (静滴 1小时 )和卡铂 15 0mg/m2 ,放疗总剂量为 6 0～ 6 5Gy/30～ 33次 /6～ 7周。结果 放疗结束后 2个月进行疗效评价。总有效率为 73 % (11/15 ) ,其中完全缓解 (CR) 2例 ,部分缓解 (PR) 9例。主要毒性反应是放射性食管炎和白细胞减少。Ⅱ度放射性食管炎 6例 ;白细胞减少Ⅱ度 2例 ,Ⅲ度 1例。 1年生存率为 5 3 .3 % (8/15 )。结论 泰素联合卡铂化疗和同步放疗对局部晚期非小细胞肺癌是一种有希望的治疗 ,有效率较高 ,毒性反应可接受。但需进一步总结远期生存率 ,建立前瞻性研究评价疗效
Objective To evaluate the efficacy and toxicity of taxol combined with carboplatin chemotherapy and concurrent radiotherapy in the treatment of locally advanced non-small cell lung cancer. Methods From July 1996 to June 1998, 15 patients with unresectable locally advanced non-small cell lung cancer were treated with Taxol combined with carboplatin chemotherapy and concurrent radiation therapy. There were 7 cases (47%) in stage IIIA, 8 cases (5 3%) in stage IIIB, 14 cases (93%) of squamous cell carcinoma, and 1 case (7%) of adenocarcinoma. On the first, 15 and 29 days after the start of radiotherapy, TAXOL 40 mg/m 2 (intravenously for 1 hour) and carboplatin 150 mg/m 2 were given, and the total dose for radiotherapy was 60-65 Gy/30-33. Times / 6 to 7 weeks. Results The curative effect was evaluated 2 months after the end of radiotherapy. The total effective rate was 73% (11/15), including 2 cases of complete remission (CR) and 9 cases of partial remission (PR). The main toxicities are radiation esophagitis and leukopenia. II degree of radiation esophagitis in 6 cases; leukopenia in 2 degrees II, III degree in 1 case. The 1-year survival rate was 53. 3% (8/15). Conclusion Taxol combined with carboplatin chemotherapy and concurrent radiotherapy is a promising treatment for locally advanced non-small cell lung cancer with high efficiency and acceptable toxicity. However, we need to further summarize the long-term survival rate and establish a prospective study to evaluate efficacy.